NovaVision, Inc.

NovaVision® provides vision solutions targeted at this substantial and largely un-addressed group of people who have lost their sight as a result of Stroke, Traumatic Brain Injury (TBI) or other neurological brain damage. NovaVision has a family of therapies that both restore and help compensate and re-train for vision loss. NovaVision’s Vision Restoration Therapy (VRT) is a therapy specifically developed to help restore lost vision resulting from Stroke or TBI, and is carried out in the comfort of a patient’s home. NovaVision’s VRT is the only FDA Cleared (510k) therapy targeted at the restoration of this type of vision loss. VRT is underpinned by 15 years of research and over 20 studies, including a 302 patient study in which notable improvements were seen in 70% of the patients. NovaVision’s NeuroEyeCoach is a compensation technique based on several decades of scientific research that is designed to teach patients to direct their gaze towards the affected area bringing previously undetected objects into sight. The patient can complete the therapy in the comfort of their own home on their own computer, in 2-4 weeks. NovaVision has put together a world class Scientific Advisory Board of distinguished professors and physicians. • Arash Sahraie (CSO), PhD - Professor and Chair in Vision Sciences at the University of Aberdeen • Alvaro Pascual-Leone, MD, PhD - Professor of Neurology at Harvard Medical School and Director of Research at the Cognitive Neurology Unit at Beth Israel Deaconess Medical Center • Joseph Zihl, PhD - Professor of Neuropsychology at the Department of Psychology, University of Munich, and Head of the Neuropsychology Research Group at the Max Planck Institute of Psychiatry • Jose Romano, MD - Chief of Stroke Division and Professor of Neurology at the University of Miami Miller School of Medicine • Jason S. Barton, MD, PhD - Professor of Neurology, Ophthalmology and Visual Sciences, University of British Columbia